Wegovy vs Ozempic vs Mounjaro: Understanding the Key Differences
When comparing Wegovy vs Ozempic vs Mounjaro, the fundamental distinction lies in their licensed indications and active ingredients. Wegovy contains semaglutide and is specifically licensed by the MHRA for weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities. Mounjaro (tirzepatide) represents a newer dual-action approach, targeting both GIP and GLP-1 receptors compared to Wegovy's GLP-1-only mechanism. Ozempic, whilst containing the same semaglutide as Wegovy, is licensed exclusively for type 2 diabetes treatment, not weight management.
The Wegovy vs Mounjaro comparison reveals two distinct pharmaceutical approaches to appetite regulation. Wegovy's semaglutide works as a GLP-1 receptor agonist, mimicking natural satiety hormones to reduce appetite and promote fullness after smaller meals. Mounjaro's tirzepatide offers dual receptor activation, potentially providing enhanced metabolic benefits through its combined GIP and GLP-1 action. Both require prescription oversight and must be used alongside a reduced-calorie diet and increased physical activity for optimal results.
Wegovy vs Mounjaro Pricing: Complete UK Cost Breakdown
Understanding the Wegovy vs Ozempic vs Mounjaro pricing landscape helps inform your treatment decision. Wegovy pricing starts at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Our Intro Duo bundle (0.25mg & 0.5mg) costs £169.99, providing your first 8 weeks of treatment. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 to access these competitive prices.
Mounjaro follows a different dosing structure with six available strengths from 2.5mg to 15mg, each requiring individual pricing consideration. The Wegovy vs Mounjaro cost comparison ultimately depends on your prescribed maintenance dose and treatment duration. Both treatments are available through our GPhC-registered pharmacy (#9012878) with identical service standards: 3-minute clinical assessment, prescriber review within 3 working days (or 24 hours with express service), and next-day cold-chain delivery once approved.
Clinical Evidence: STEP Trials and Treatment Outcomes
The clinical foundation for Wegovy vs Ozempic vs Mounjaro comparisons stems from robust trial data, though direct head-to-head studies remain limited. In clinical trials, patients taking Wegovy alongside diet and exercise achieved an average of ~clinically studied weight loss at 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021), compared to ~2.4% with placebo. The STEP programme demonstrated consistent efficacy across different populations, including ~9.6% average weight loss in patients with type 2 diabetes (STEP 2).
Mounjaro's clinical profile emerges from separate trial programmes with different methodologies, making direct percentage comparisons inappropriate. When evaluating Wegovy vs Mounjaro options, your prescriber considers individual factors including BMI, comorbidities, and treatment goals rather than comparing trial percentages across different study designs. Both treatments require clinical assessment to ensure appropriate use within their licensed indications.
How Wegovy Works: GLP-1 Mechanism Explained
Wegovy's semaglutide operates as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a natural hormone released when you eat. This mechanism reduces appetite by acting on brain centres that control hunger and satiety, helping you feel fuller after consuming smaller portions. The treatment may also slow gastric emptying, prolonging the sensation of fullness between meals. Unlike rapid-acting appetite suppressants, Wegovy provides sustained appetite regulation throughout the week with once-weekly dosing. This mechanism explains why Wegovy must be used alongside a reduced-calorie diet and increased physical activity, as it enhances but doesn't replace healthy lifestyle changes.
Ordering Process: From Assessment to Delivery
Accessing Wegovy vs Mounjaro through EverydayMeds begins with our 3-minute online clinical assessment, designed to evaluate your suitability for weight management treatment. Our qualified prescribers review your information within 3 working days (or 24 hours with express service), ensuring each prescription meets clinical safety standards. Once approved, your chosen treatment ships via next-day delivery using our temperature-controlled cold-chain system, maintaining the integrity of your prescription-only medicine throughout transit. Our process includes ongoing clinical monitoring, with prescribers available to adjust your treatment plan as needed. The entire system operates under our GPhC registration (#9012878), providing regulated pharmaceutical care from assessment through to delivery.
Storage and Practical Considerations
The Wegovy vs Mounjaro comparison includes important practical differences affecting daily use and travel. Wegovy requires refrigerated storage at 2–8°C before first use but offers significant flexibility with 6 weeks of room temperature stability below 30°C once removed from the fridge. Mounjaro provides only 21 days at room temperature, making Wegovy more suitable for extended travel or flexible storage situations. Both treatments use pre-filled pen injectors, though Wegovy's FlexTouch pen system offers dose escalation from 0.25mg through to 2.4mg maintenance dosing. The mandatory dose escalation schedule prevents skipping doses, ensuring gradual tolerance development and minimising potential side effects during treatment initiation.
Wegovy vs Mounjaro: Dual vs Single Receptor Targeting
The fundamental pharmacological difference in Wegovy vs Ozempic vs Mounjaro comparisons centres on receptor selectivity and metabolic pathways. Wegovy's semaglutide provides targeted GLP-1 receptor agonism with established clinical experience and predictable dose-response relationships. This single-pathway approach offers straightforward treatment monitoring and well-documented safety profiles from extensive real-world use.
Mounjaro's tirzepatide introduces dual GIP and GLP-1 receptor activation, potentially offering enhanced metabolic benefits through multiple pathways. This dual-action mechanism may provide different appetite regulation patterns and metabolic effects compared to Wegovy's GLP-1-only approach. Your prescriber can evaluate which mechanism aligns better with your individual metabolic profile and treatment goals, as both options remain available through our comprehensive weight management service.
Making Your Treatment Choice with Expert Support
Deciding between Wegovy vs Mounjaro requires individualised clinical assessment rather than generic comparisons. Our clinical team evaluates your medical history, current medications, BMI, and weight-related comorbidities to recommend the most appropriate treatment option. Both Wegovy and Mounjaro are available from EverydayMeds, ensuring you can access either treatment through our established prescription service. New customers use discount code FIRST40 at checkout, whilst returning customers apply DOSE25 to access competitive pricing across our complete range. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment, with expert prescriber support available throughout your weight management journey. Our regulated approach ensures you receive genuine prescription-only medicines with ongoing clinical oversight and convenient next-day delivery service.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026